Previous 10 | Next 10 |
- Revised the Minimum Liquidity Covenant for All Times Following October 31, 2023 to be Between US$15 Million and US$20 Million - Minimum Quarterly Revenue Covenant Replaced with Minimum Adjusted EBITDA Covenant - Deleted Prohibition Against Having a Going Concern Note in the Op...
2023-10-13 08:46:37 ET More on Theratechnologies Inc., Theratechnologies, etc. Theratechnologies Inc. (THTX) Q3 2023 Earnings Call Transcript Historical earnings data for Theratechnologies Inc. Financial information for Theratechnologies Inc. Seeking Alpha...
Significant reduction in INSTI-associated VAT accumulation with tesamorelin contrasts with VAT increase in patients taking placebo VAT accumulation observed after 12 months on INSTI-containing regimens, even in the absence of significant weight or body mass index changes R...
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Theratechnologies I...
Milestone for Company’s lead peptide-drug conjugate candidate follows FDA acceptance of protocol amendment for Phase 1 study on June 2, 2023 MONTREAL, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: T...
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc...
2023-09-26 11:44:09 ET Theratechnologies Inc. (THTX) Q3 2023 Earnings Conference Call September 26, 2023, 08:30 AM ET Company Participants John Mullaly - Investor Relations Paul Levesque - President and Chief Executive Officer Philip Dubuc - Senior Vice President...
2023-09-26 07:40:24 ET More on Theratechnologies Seeking Alpha’s Quant Rating on Theratechnologies Historical earnings data for Theratechnologies Financial information for Theratechnologies Theratechnologies Inc. (THTX) Q2 2023 Earnings Call Transcript...
Q3 2023 consolidated revenue of $20.9 million, adjusted EBITDA of $2.2 million sBLA for F8 formulation of tesamorelin submitted to FDA Agreement in principle on key amendments to loan facility with Marathon MONTREAL, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (&...
Nanobiotix S.A. (NBTX) is expected to report for Q2 2023 Wal-mart de Mexico S A B de C V ADR (WMMVY) is expected to report for Q2 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q1 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-...
News, Short Squeeze, Breakout and More Instantly...
Theratechnologies Inc. Company Name:
THTX Stock Symbol:
NYSE Market:
Theratechnologies Inc. Website:
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...